Chris Anthony

Chris Anthony

Auto-generated profile, based on publicly available information

Chris Anthony

Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, Unites States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SPSaberio Lo Presti
Saberio Lo Presti
TETarec K. Elajami
Tarec K. Elajami
RRReza Reyaldeen
Reza Reyaldeen
CAChris Anthony
Chris Anthony
MIMassimo Imazio
Massimo Imazio
AKAllan L. Klein
Allan L. Klein
Recurrent pericarditis (RP) is a complex inflammatory disorder associated with adverse outcomes and poor quality of life. After the first episode of acute pericarditis, a non‐negligible group of patients will fail to achieve complete remission despite treatment and will be challenged by side effects from the chronic use of medications like corticosteroids. The cause of RP remains unknown in the majority of cases, mainly due to a gap in knowledge of its complex pathophysiology. Over the past 2 decades, the interleukin‐1 (IL‐1) pathway has been uncovered as a key element in the inflammatory cascade, allowing the development of pharmacological targets known as IL‐1 inhibitors. This group of medications has emerged as a treatment option for patients with RP colchicine‐resistance and steroid dependents. Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP. Although further studies are needed to refine therapeutic protocols and taper of concomitant therapies, IL‐1 inhibitors, continue to consolidate as part of the pharmacological armamentarium to manage this complex condition with potential use as monotherapy. The aim of this review is to highlight the role of IL‐1 pathway in RP and discuss the efficacy, safety, and clinical applicability of IL‐1 inhibitors in the treatment of RP based on current evidence.

8 November 2020 in Heart, Lung and Circulation
Verified
Journal Article
Open access
PDF file
CAC. Anthony
C. Anthony
MIMuhammad Imran
Muhammad Imran
JPJ. Pouliopoulos
J. Pouliopoulos
SES. Emmanuel
S. Emmanuel
JIJ. Iliff
J. Iliff
AJA. Jabbour
A. Jabbour
To determine whether cardiovascular magnetic resonance (CMR)-based surveillance for cardiac allograft rejection in the first year after cardiac transplantation is safe compared to traditional endomyocardial biopsy (EMBx)-based surveillance.


1 January 2022
Verified
Book Chapter
Closed access
ARAhmed Abdel razek
Ahmed Abdel razek
OAOlusola Adekoya
Olusola Adekoya
LALakshmi Alagarsamy
Lakshmi Alagarsamy
HAHala Al-Marsafawy
Hala Al-Marsafawy
SASalah S. Al-Zaiti
Salah S. Al-Zaiti
BXBo Xu
Bo Xu

1 May 2021 in JACC
Verified
Journal Article
Closed access
HLHassan Mehmood Lak
Hassan Mehmood Lak
CAChris Anthony
Chris Anthony
MFMuhammad Furqan
Muhammad Furqan
MGMohamed Gad
Mohamed Gad
SCSanchit Chawla
Sanchit Chawla
AKAllan Klein
Allan Klein